The most-favored-nation pricing regime is no longer a large-cap experiment. The administration has now reached drug pricing deals with 26 pharmaceutical companies, including Pfizer, Eli Lilly, and Novo Nordisk, as part of its most-favored-nation policy. The agreements cover 89% of the branded drug market. The nine companies added on August 31 were mostly midsized names: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The policy now touches generics, specialty biologics, and essential medicines alike.
The Bigger Trend
The agreements are for so-called most-favored-nation prices, meaning that Medicaid will pay prices tied to what other countries pay. A 2024 RAND Corp. analysis using 2022 data found that U.S. prescription drug prices averaged nearly 2.8 times those in comparison countries, while brand-name drug prices were more than three times as high after accounting for estimated rebates. Closing that gap has been the stated goal all along. What changed on August 31 is that the program now has enough industry coverage to function as a structural floor, not a headline initiative.
The nine new manufacturers committed to invest at least $19.6 billion collectively in U.S. manufacturing, and several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve to reduce reliance on foreign nations. In exchange, the companies receive relief from pharmaceutical tariffs. That trade shapes the long-run competitive landscape as much as the pricing terms themselves.
The Investment Case: Dividend Stocks in a Priced World
Income investors who own Pfizer or Amgen for yield need to hold two things in their heads at once. Pfizer has already absorbed the policy into its numbers: the company reaffirmed full-year 2026 revenue guidance of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. Amgen, meanwhile, beat second-quarter earnings estimates, with quarterly revenue rising 10% year over year to $10.1 billion. Neither company’s dividend looks endangered today, but neither has unlimited pricing runway going forward.
The more interesting angle is what the policy does to health insurers and pharmacy benefit managers. By allowing patients to bypass traditional PBM middlemen and access most-favored-nation pricing directly from manufacturers, the TrumpRx platform threatens the traditional rebate-driven profit model. CVS responded by adapting rather than resisting: CVS announced it would accept TrumpRx discount cards across its 9,000 retail locations, prioritizing pharmacy foot traffic and dispensing fees over the protection of its Caremark PBM’s rebate spread. That is a genuine strategic pivot, and its long-term effect on earnings is still being priced in.
CVS has paid cash dividends every quarter since becoming a public company. The quarterly payout now stands at $0.665 per share, or $2.66 annualized, with a yield more than twice the S&P 500 average. Cigna raised its quarterly dividend to $1.56 per share in early 2026, an increase from the 2025 cash quarterly dividend of $1.51 per share. Both payouts look intact for now. But key risks include ongoing PBM regulation, medical cost inflation in stop-loss and specialty drugs, and the earnings step-down associated with the shift to a rebate-reduced model.
Building Wealth Around This Idea
This is not a moment to abandon dividend-paying pharmaceutical and health-insurance names. It is a moment to understand which ones are running toward the new pricing environment and which are still negotiating with it. CVS has moved early toward transparent cost-based models. Cigna’s Express Scripts reached a settlement with the FTC and is under a more fee-based, delinked structure in parts of its book. Some critics note that after most-favored-nation deals, companies often raise prices in other countries so that the prices the U.S. compares to will be higher over time. That dynamic could soften the revenue impact for large branded-drug manufacturers if it holds.
Position sizing matters here more than stock selection. A concentrated bet on any single pharma dividend payer carries policy risk that a diversified allocation across large-cap manufacturers, generic specialists like Teva, and vertically integrated health services companies like CVS does not.
Risks to Monitor
Trump’s requests for Congress to enact legislation to make MFN pricing mandatory has run into headwinds from pharmaceutical lobbyists and some lawmakers. That means the agreements remain voluntary and theoretically reversible under a future administration, which is itself a risk worth pricing into any long-horizon thesis. On the insurer side, regulatory and reimbursement uncertainty for the PBM and retail pharmacy businesses remains the key risk and does not disappear with the latest drug pricing news.
Daily Wealth Takeaway
When a policy regime shifts from targeting a handful of household names to covering nearly the entire industry, the investment story stops being about which companies signed and starts being about which business models survive the transition intact. The dividend checks from the strongest players in this space are not in immediate danger. The rebate-driven fee structures that once padded those earnings quietly are.
